Shoreline Biosciences

company

About

Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients.

  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$140M
Industries
Biotechnology,Health Care,Life Science,Medical
Founded date
Jan 1, 2020
Number Of Employee
1 - 10
Operating Status
Active

Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients. Its proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.

The company was founded in 2020 and is headquartered in La Jolla, CA, USA.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$183M
Shoreline Biosciences has raised a total of $183M in funding over 2 rounds. Their latest funding was raised on Nov 2, 2021 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 2, 2021 Series B $140M 3 Detail
Feb 7, 2021 Series A $43M 2 Detail

Investors

Number of Lead Investors
Number of Investors
4
Shoreline Biosciences is funded by 4 investors. Kite Pharma and BeiGene are the most recent investors.
Investor Name Lead Investor Funding Round
Kite Pharma Series B
BeiGene Series B
Superstring Capital Series B
Gilead Capital Series A